//=time() ?>
From the February issue: In vivo epigenetic #CRISPR screen identifies Asf1a as an immunotherapeutic target in #Kras-mutant lung adenocarcinoma @nyulangone @nyuschoolofmed #LungCancer #immunotherapy https://t.co/cOCYGhz1Y9